Real Endpoints

Real Endpoints believes that the single biggest challenge to the long-term health of medical innovation is getting it paid for. In a world where healthcare decision-making is increasingly concentrated in a consolidating set of ever-more powerful industrial customers, RE focuses entirely on delivering solutions that enhance appropriate access to innovation. To do this, we leverage insights from our close working relationships with payers and biopharma; objective, data-driven proprietary tools; and above all the creativity and deep experience of our people. In particular, RE focuses on three main activities: Helping to define, through objective clinical and economic assessment and practical evidence...

Market access,cell & gene therapy,pricing and reimbursement,market access organizational design,drug distribution,value based contracting,patient and hub services benchmarking,hta and icer preparation,contracting strategies,and payor engagement strategies

Real endpoints operates in the Pharmaceutical manufacturing industry.

Real endpoints's revenue is 11m - 100m

Real endpoints has 11 - 50 employees.